Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BioChemics (BCI).
John Masiz, president & CEO of BioChemics, said: “Based on the nature of this disease, we believe that the combination of Nanobac’s active pharmaceutical agent combined with BCI’s drug delivery technology may provide a more efficacious treatment therapy for patients suffering from prostatitis.”